Noelle Hutchins

With iPSC therapies facing high upfront costs, complex manufacturing demands, and evolving investor sentiment, early alignment across pharma, VCs, and funding stakeholders is critical. This panel will explore how to strategically de-risk clinical development, secure funding, and build commercially viable cell therapy programs in a capital-intensive landscape.

• How to engage pharma BD, VCs, and payers early to overcome the “elephant in the room”, high cost of goods and long development timelines
• What investors look for in scalable, robust iPSC manufacturing strategies before committing capital
• Coordinating government funding, venture investment, and pharma partnerships to support sustainable clinical and commercial success